Modulation of T-Cell Co-Stimulation in Rheumatoid Arthritis
暂无分享,去创建一个
[1] Zoe Stableford,et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). , 2006, Rheumatology.
[2] E. Keystone,et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.
[3] S. Paget,et al. Predominantly T-cell infiltrate in rheumatoid synovial membranes. , 1975, The New England journal of medicine.
[4] C. Bombardier,et al. Quality of life in patients with rheumatoid arthritis: does abatacept make a difference? , 2007, Clinical and experimental rheumatology.
[5] B. Dijkmans,et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.
[6] H. Genant,et al. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis , 2006, Annals of Internal Medicine.
[7] L. Moreland,et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate , 2004, Annals of the rheumatic diseases.
[8] P. Gordon,et al. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. , 2001, The Journal of rheumatology.
[9] C. Birbara,et al. Frequency, Predictors, and Economic Impact of Upward Dose Adjustment of Infliximab in Managed Care Patients With Rheumatoid Arthritis , 2005, Journal of managed care pharmacy : JMCP.
[10] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[11] G. Newsome. Guidelines for the management of rheumatoid arthritis: 2002 update. , 2002, Journal of the American Academy of Nurse Practitioners.
[12] R. Cervera,et al. Is there a microangiopathic antiphospholipid syndrome? , 2006, Annals of the rheumatic diseases.
[13] P. V. van Riel,et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study , 2006, Annals of the rheumatic diseases.
[14] P. Emery,et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment , 2006, Annals of the rheumatic diseases.
[15] M. Dougados,et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.
[16] A. Silman,et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. , 2007, Arthritis and rheumatism.
[17] B. Hernández-Cruz,et al. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. , 2007, Rheumatology.
[18] G. Panayi,et al. Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.
[19] D. M. van der Heijde,et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.
[20] R S Wallis,et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] M. Dougados,et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.
[22] B. Cortet,et al. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. , 2006, Rheumatology.
[23] E. Tindall,et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.
[24] J. Gómez-Reino,et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.
[25] M. Weinblatt,et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. , 2006, Arthritis and rheumatism.
[26] L. Moreland,et al. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis , 2005, Expert opinion on biological therapy.
[27] P. Linsley,et al. Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions* , 1996, The Journal of Biological Chemistry.
[28] M. Dougados,et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy , 2007, Annals of the rheumatic diseases.
[29] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[30] H. Genant,et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. , 2008, Arthritis and rheumatism.
[31] J. Sibilia,et al. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.
[32] Richard W. Martin,et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.
[33] M. Liang,et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. , 2006, Arthritis and rheumatism.
[34] Stanley B. Cohen,et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. , 2002, Arthritis and rheumatism.
[35] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[36] H. Genant,et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial , 2007, Annals of the rheumatic diseases.
[37] Joseph Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .
[38] P. Linsley,et al. Treatment of murine lupus with CTLA4Ig. , 1994, Science.
[39] C. Peterfy,et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. , 2006, Arthritis and rheumatism.
[40] R. Yood,et al. Guidelines for the management of rheumatoid arthritis: 2002 Update. , 2002, Arthritis and rheumatism.
[41] J. Allison,et al. CTLA-4-Mediated inhibition of early events of T cell proliferation. , 1999, Journal of immunology.
[42] M. Dougados,et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.
[43] P. M. Davis,et al. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. , 2008, Clinical immunology.
[44] L. Klareskog,et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.
[45] M. Dougados,et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.
[46] A. Rozelle,et al. Efficacy results from pivotal clinical trials with abatacept. , 2007, Clinical and experimental rheumatology.
[47] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[48] J. Kremer,et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial , 2006, Annals of the rheumatic diseases.
[49] M. Feldmann,et al. Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2 , 1996, European journal of immunology.
[50] D. M. van der Heijde,et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. , 2006, Arthritis and rheumatism.
[51] H. Reiser,et al. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. , 1996, The New England journal of medicine.